Oral antibiotic to treat soft tissue, dental and bone infections caused by susceptible strains of bacteria in dogs
The only FDA veterinary approval of all four dosage strengths: 25mg, 75mg, 150mg & 300mg
Clindamycin Hydrochloride Capsules, USP for use in dogs only, are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below:
Skin infections (wounds and abscesses) due to coagulase positive staphylococci (Staphylococcus aureus or Staphylococcus intermedius).
Deep wounds and abscesses due to Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens.
Dental infections due to Staphylococcus aureus, Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens.
Osteomyelitis due to Staphylococcus aureus, Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens.
FDA approved under ANDA #200-298, this product is considered bioequivalent to the reference product, Antirobe®.
• 25 mg – 200 count bottles
• 75 mg – 200 count bottles
• 150 mg – 100 & 500 count bottles
• 300 mg – 100 count bottles
For more information about Cronus Pharma products please contact your authorized distributor.
1 (844) 227-6687
Cronus Pharma LLC is a fully integrated R&D, manufacturing, and marketing animal health pharmaceutical company located in East Brunswick, New Jersey. Dedicated to providing quality and cost-effective pharmaceuticals to the U.S. animal health market, our products are accessible to all veterinarians and pet owners through national and regional distributors.
Cronus Pharma © 2021 All Rights Reserved. Antirobe® is a trademark of Zoetis Services LLC.